{
    "clinical_study": {
        "@rank": "50338", 
        "arm_group": [
            {
                "arm_group_label": "AF219 and placebo", 
                "arm_group_type": "Experimental", 
                "description": "AF219 50 mg tablet and placebo (for AF219) tablet by mouth twice daily for 3.5 days"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo (for AF219) tablets by mouth twice daily for 3.5 days"
            }, 
            {
                "arm_group_label": "AF219 300 mg and placebo", 
                "arm_group_type": "Experimental", 
                "description": "AF219 300 mg tablet and placebo (for AF219) tablet by mouth twice daily for 3.5 days"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomised, double blind, double-dummy, placebo-controlled, three way crossover,\n      single centre study in subjects with asthma undergoing inhalation of methacholine and ATP to\n      assess the PC20 response of two dose levels of AF-219 compared with placebo."
        }, 
        "brief_title": "A Study to Evaluate the Effect of AF-219 on Methacholine Hyper-reactivity in Subjects With Asthma", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Asthma", 
        "condition_browse": {
            "mesh_term": "Asthma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Non-smokers or former smokers, who stopped smoking 6 months prior to screening. Former\n        smokers should not have a smoking history of more than 5 pack years (1 pack of 20\n        cigarettes per day over 5 years).\n\n        Pre-bronchodilator (after abstaining from Short acting \u03b22-agonist for \u22658 hrs) Forced\n        Expiratory Volume (FEV1) \u226570% of the predicted normal value at the screening visit.\n\n        Pre-bronchodilator (after abstaining from Short acting \u03b22-agonist for \u22658 hrs) Forced\n        Expiratory Volume (FEV1) \u226570% of the predicted normal value OR if less than 70% must be\n        within +/- 12 % of screening FEV1 prior to randomization.\n\n        History or diagnosis of asthma for at least 6 months prior to screening according to the\n        Global Initiative in Asthma guidelines (GINA, 2012).\n\n        Use of Short acting \u03b22-agonist therapy only (\u2264 8 puffs per day) for at least 4 weeks prior\n        to screening and prior to randomisation.\n\n        Positive response to methacholine challenge (PC20 \u2264 8 mg/mL) at screening.\n\n        Positive response to ATP challenge (PC20 \u2264 200 \u00b5mol/mL) at screening.\n\n        Exclusion Criteria:\n\n        Hospitalized or attended the emergency department for an asthma attack in the 12 months\n        prior to screening.\n\n        Exacerbation of asthma or lower respiratory tract infection during the 4 weeks before\n        screening.\n\n        Upper respiratory tract infection during the 4 weeks before screening or prior to\n        randomization requiring treatment with antibiotics.\n\n        Inhaled or systemic corticosteroids (oral, intravenous, intramuscular) within 4 weeks\n        prior to screening.\n\n        Short-acting or long-acting antihistamines within 48hrs or 7 days, respectively, prior to\n        screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993329", 
            "org_study_id": "AF219-009"
        }, 
        "intervention": [
            {
                "arm_group_label": "AF219 and placebo", 
                "intervention_name": "AF219 50 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "AF219 300 mg and placebo", 
                "intervention_name": "AF219 300 mg", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "AF219 and placebo", 
                    "Placebo", 
                    "AF219 300 mg and placebo"
                ], 
                "description": "sugar pill manufactured to mimic AF219 50 mg and 300 mg tablets", 
                "intervention_name": "Placebo (for AF219)", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methacholine Chloride"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "November 20, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Manchester", 
                    "country": "United Kingdom", 
                    "zip": "M23 9QZ"
                }, 
                "name": "Medicines Evaluation Unit"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Randomised, Double-Blind, Double-Dummy, Placebo-Controlled, Three-Way Cross-over Study to Evaluate the Effect of AF-219 on Methacholine Hyper-reactivity in Subjects With Asthma", 
        "overall_official": {
            "affiliation": "Medicines Evaluation Unit", 
            "last_name": "Dave Singh, MRCP, MD, CCST", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "PC20 response of two dose levels of AF-219 compared with placebo in subjects with asthma after provocation with methacholine", 
            "safety_issue": "No", 
            "time_frame": "3.5 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993329"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "PC20 response of two dose levels of AF-219 compared with placebo in subjects with asthma after provocation with inhaled ATP.", 
            "safety_issue": "No", 
            "time_frame": "3.5 days"
        }, 
        "source": "Afferent Pharmaceuticals, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Afferent Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}